PLUS THERAPEUTICS 8-K: Item 5.02 Event Reported
Ticker: PSTV · Form: 8-K · Filed: Mar 26, 2026 · CIK: 0001095981
| Field | Detail |
|---|---|
| Company | Plus Therapeutics, Inc. (PSTV) |
| Form Type | 8-K |
| Filed Date | Mar 26, 2026 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: executive-change, corporate-governance, compensation
TL;DR
**PLUS THERAPEUTICS filed an 8-K for an Item 5.02 event, signaling potential executive or compensation changes.**
AI Summary
PLUS THERAPEUTICS, INC. filed an 8-K on March 26, 2026, reporting an event under Item 5.02, which typically relates to changes in directors or officers or their compensation. While the filing details are not fully provided in the excerpt, the company's business address is 4200 Marathon Blvd., Suite 200, Austin, TX 78756. This matters to investors because changes in leadership or executive compensation can signal strategic shifts, financial health, or potential instability, all of which can influence stock performance.
Why It Matters
Changes in executive leadership or compensation can significantly impact a company's strategic direction and financial stability, directly affecting investor confidence and stock valuation.
Risk Assessment
Risk Level: medium — An Item 5.02 filing can indicate significant changes in management or compensation, which introduces uncertainty and potential risk for investors.
Analyst Insight
A smart investor would monitor for subsequent announcements from PLUS THERAPEUTICS, INC. that provide specific details regarding the Item 5.02 event, as these details will clarify the impact on the company's future operations and leadership stability.
Key Players & Entities
- PLUS THERAPEUTICS, INC. (company) — the filer of the 8-K
- 0001095981 (company) — CIK of PLUS THERAPEUTICS, INC.
- 2026-03-26 (date) — filing date of the 8-K
- 4200 MARATHON BLVD. SUITE 200 AUSTIN TX 78756 (company) — business address of PLUS THERAPEUTICS, INC.
Forward-Looking Statements
- The company will announce specific changes to its board or executive team. (PLUS THERAPEUTICS, INC.) — medium confidence, target: 2026-04-26
- Details regarding executive compensation adjustments will be disclosed. (PLUS THERAPEUTICS, INC.) — medium confidence, target: 2026-04-26
FAQ
What is the purpose of an 8-K filing, specifically for Item 5.02?
An 8-K filing is used to announce major events that shareholders should know about. Item 5.02 specifically covers 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers,' meaning it reports changes in the company's leadership or how they are paid.
When was this 8-K filing submitted and accepted by the SEC?
This 8-K filing was submitted and accepted by the SEC on March 26, 2026, at 08:33:06.
What is the CIK (Central Index Key) for PLUS THERAPEUTICS, INC.?
The CIK for PLUS THERAPEUTICS, INC. is 0001095981.
What is the business address of PLUS THERAPEUTICS, INC. as stated in the filing?
The business address of PLUS THERAPEUTICS, INC. is 4200 MARATHON BLVD. SUITE 200 AUSTIN TX 78756.
What is the SIC (Standard Industrial Classification) code for PLUS THERAPEUTICS, INC.?
The SIC code for PLUS THERAPEUTICS, INC. is 3841, which corresponds to 'Surgical & Medical Instruments & Apparatus'.
Filing Stats: 1,018 words · 4 min read · ~3 pages · Grade level 10.3 · Accepted 2026-03-26 08:33:06
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share PSTV The Nasdaq Capital M
Filing Documents
- pstv-20260320.htm (8-K) — 51KB
- 0001193125-26-125195.txt ( ) — 163KB
- pstv-20260320.xsd (EX-101.SCH) — 30KB
- pstv-20260320_htm.xml (XML) — 5KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PLUS THERAPEUTICS, INC. Date: March 26, 2026 By: /s/ Marc H. Hedrick, M.D. Marc H. Hedrick, M.D. President and Chief Executive Officer